CoChat

Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Understanding the kinetics and durability of AAV-mediated transgene expression in the brain is essential for conducting basic neuroscience studies as well as for developing gene therapy approaches for CNS diseases. Here, we characterize and compare the temporal profile of transgene expression after bilateral injections into the mouse striatum of rAAV9 encoding GFP under the control of either a ubiquitous promoter (CAG), or the neuron-specific human synapsin (hSyn) and CamKII promoters. GFP protein expression with the CAG promoter was highest at 3 weeks, and then decreased to stable levels at 3 and 6 months. Surprisingly, GFP mRNA levels continued to increase from 3 weeks to 3 months, despite GFP protein expression decreasing during this time. GFP protein expression with hSyn increased more slowly, reaching a maximum at 3 months, which was equivalent to protein expression levels from CAG at that time point. Importantly, transgene expression driven by the hSyn promoter at 6 months was not silenced as previously reported, and GFP mRNA was continuing to rise even at the final 6-month time point. Thus, hSyn as a promoter for transgene expression demonstrates long-term durability but may require more time after vector administration to achieve steady-state levels. Because CAG had the highest GFP protein expression in our comparison, which was at 3 weeks post administration, the early kinetics of transgene expression from CAG was examined (1, 2, 5, and 10 days after injection). This analysis showed that GFP protein expression and GFP mRNA increased during the first 3 weeks after administration. Interestingly, vector DNA rapidly decreased 10-fold over the first 3 weeks following injection as it assembled into stable circular episomes and concatemers. Surprisingly, the processing of vector genomes into circular episomes and concatemers was continually dynamic up to 3 months after injection. These results provide novel insight into the dynamic processing of vector genomes and promoter-specific temporal patterns of transgene expression in the brain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fneur.2022.1051559

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Diagram of in vivo experimental paradigm. (A) rAAV9 encoding GFP under the promoters CAG, hSyn, or CamKII were stereotaxically injected into the striatum of adult (at least 6 weeks of age), female C57BL/6 mice bilaterally. At various time points after AAV administration, mice were euthanized, perfused with saline, and the brains were collected. The right hemisphere of the brain was fixed in 4% PFA, cryoprotected in a 30% sucrose solution, and sectioned using a microtome for histological analyses. The striatum from the left hemisphere was micro-dissected and frozen. DNA and RNA was extracted from each striatum. cDNA was synthesized from the RNA. The number of AAV genome copies per cell and GFP transcripts were determined using ddPCR. (B) Diagram depicting circular AAV genome quantification assay. Total DNA is extracted from tissues and treated with PS-DNASE which digests all linear AAV genomes. Only circular AAV genomes are left behind. Quantification of this population of AAV genomes on ddPCR gives number of circular AAV genomes containing an AAV genome. This does not account for different sized AAV concatemers due to an end point measurement nature of ddPCR and thus measures total number of circular DNA with an AAV genome. To quantify number of AAV genomes in a circular format, the PS-DNASE digested samples are further digested with ECORI. ECORI cuts a single time between the promoter and EGFP sequences. Concatemers with multiple AAV genomes will be digested into multiple AAV linear genome subunits. Quantification of this population of AAV genomes with ddPCR will accurately give number of AAV genomes in a circular format. Created using images from BioRender.com.
Figure 1 Diagram of in vivo experimental paradigm. (A) rAAV9 encoding GFP under the promoters CAG, hSyn, or CamKII were stereotaxically injected into the striatum of adult (at least 6 weeks of age), female C57BL/6 mice bilaterally. At various time points after AAV administration, mice were euthanized, perfused with saline, and the brains were collected. The right hemisphere of the brain was fixed in 4% PFA, cryoprotected in a 30% sucrose solution, and sectioned using a microtome for histological analyses. The striatum from the left hemisphere was micro-dissected and frozen. DNA and RNA was extracted from each striatum. cDNA was synthesized from the RNA. The number of AAV genome copies per cell and GFP transcripts were determined using ddPCR. (B) Diagram depicting circular AAV genome quantification assay. Total DNA is extracted from tissues and treated with PS-DNASE which digests all linear AAV genomes. Only circular AAV genomes are left behind. Quantification of this population of AAV genomes on ddPCR gives number of circular AAV genomes containing an AAV genome. This does not account for different sized AAV concatemers due to an end point measurement nature of ddPCR and thus measures total number of circular DNA with an AAV genome. To quantify number of AAV genomes in a circular format, the PS-DNASE digested samples are further digested with ECORI. ECORI cuts a single time between the promoter and EGFP sequences. Concatemers with multiple AAV genomes will be digested into multiple AAV linear genome subunits. Quantification of this population of AAV genomes with ddPCR will accurately give number of AAV genomes in a circular format. Created using images from BioRender.com.CC BY · PubMed Central
Figure 2 Long-term kinetics of rAAV9 genomes, transcripts and protein expression in the striatum in mice stereotaxically injected with rAAV9-CAG-GFP, rAAV9-hSyn-GFP, or rAAV9-CamKII-GFP. (A) Images and (B) quantification of luminance of native GFP fluorescence (500 ms exposure) at 3 weeks, 3 and 6 months after rAAV9-GFP administration. Scale bar represents 3 mm. (C) Amount of GFP mRNA relative to TBP mRNA and (D) GFP DNA copies per cell as determined by copy of GFP to two glucagon copies per cell. Data was analyzed using a two-way ANOVA followed by Tukey's multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, and #p < 0.0001.
Figure 2 Long-term kinetics of rAAV9 genomes, transcripts and protein expression in the striatum in mice stereotaxically injected with rAAV9-CAG-GFP, rAAV9-hSyn-GFP, or rAAV9-CamKII-GFP. (A) Images and (B) quantification of luminance of native GFP fluorescence (500 ms exposure) at 3 weeks, 3 and 6 months after rAAV9-GFP administration. Scale bar represents 3 mm. (C) Amount of GFP mRNA relative to TBP mRNA and (D) GFP DNA copies per cell as determined by copy of GFP to two glucagon copies per cell. Data was analyzed using a two-way ANOVA followed by Tukey's multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, and #p < 0.0001.CC BY · PubMed Central
Figure 3 Cell-type specificity of GFP expression in the striatum of mice. (A) Colocalization of GFP expression with markers of neurons [NeuN] and astrocytes [S100β]. Arrows point out cells with co-localization of GFP with NeuN (white) and S100B (yellow). Percentage of (B) neurons and (C) astrocytes that express GFP in the transduced area. (D) Colocalization of GFP expression with markers of oligodendrocytes (Olig2) and (E) percentage of oligodendrocytes that express GFP in the transduced area. White arrows point out cells with co-localization of GFP with Olig2. (F) Colocalization of GFP expression with markers of microglia (Iba1) and (G) percentage of microglia that express GFP in the transduced area. Scale bar represents 50 μm. Data was analyzed using a one-way ANOVA followed by Tukey's multiple comparisons test. ***p < 0.001 and #p < 0.0001.
Figure 3 Cell-type specificity of GFP expression in the striatum of mice. (A) Colocalization of GFP expression with markers of neurons [NeuN] and astrocytes [S100β]. Arrows point out cells with co-localization of GFP with NeuN (white) and S100B (yellow). Percentage of (B) neurons and (C) astrocytes that express GFP in the transduced area. (D) Colocalization of GFP expression with markers of oligodendrocytes (Olig2) and (E) percentage of oligodendrocytes that express GFP in the transduced area. White arrows point out cells with co-localization of GFP with Olig2. (F) Colocalization of GFP expression with markers of microglia (Iba1) and (G) percentage of microglia that express GFP in the transduced area. Scale bar represents 50 μm. Data was analyzed using a one-way ANOVA followed by Tukey's multiple comparisons test. ***p < 0.001 and #p < 0.0001.CC BY · PubMed Central
Figure 4 Long-term kinetics of rAAV9-CAG-GFP in the striatum in mice. (A) Quantification of luminance from native GFP fluorescence (500 ms exposure) during the first 6 months after rAAV9-CAG-GFP administration. (B) ddPCR analysis measuring the amount of GFP mRNA relative to TBP mRNA and (C) GFP DNA copies per cell as determined by copy numbers of GFP to two glucagon copies per cell during the first 6 months after administration of rAAV9-CAG-GFP. Data from 3 weeks, 3 and 6 months was previously presented in Figure 2. (D) The number of circular DNA units that contain an AAV genome (not considering concatemers) per cell, (E) the total number of AAV genomes in circular DNA per cell (diploid genome) and (F) the average number of AAV genomes per circular episome [values from (E) divided by values from (D)] in the striatum of mice during the first 6 months after administration of rAAV9-CAG-GFP. Data was analyzed using a one-way ANOVA followed by Tukey's multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, and #p < 0.0001. Significance symbols in parentheses are compare with day 1.
Figure 4 Long-term kinetics of rAAV9-CAG-GFP in the striatum in mice. (A) Quantification of luminance from native GFP fluorescence (500 ms exposure) during the first 6 months after rAAV9-CAG-GFP administration. (B) ddPCR analysis measuring the amount of GFP mRNA relative to TBP mRNA and (C) GFP DNA copies per cell as determined by copy numbers of GFP to two glucagon copies per cell during the first 6 months after administration of rAAV9-CAG-GFP. Data from 3 weeks, 3 and 6 months was previously presented in Figure 2. (D) The number of circular DNA units that contain an AAV genome (not considering concatemers) per cell, (E) the total number of AAV genomes in circular DNA per cell (diploid genome) and (F) the average number of AAV genomes per circular episome [values from (E) divided by values from (D)] in the striatum of mice during the first 6 months after administration of rAAV9-CAG-GFP. Data was analyzed using a one-way ANOVA followed by Tukey's multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, and #p < 0.0001. Significance symbols in parentheses are compare with day 1.CC BY · PubMed Central
Figure 5 Model of rAAV9 genome processing and transgene expression. (A) Linear single-stranded rAAV DNA is transported to the nucleus and then converted to linear double-stranded genomes by second-strand synthesis or strand annealing. Linear double-stranded genomes are converted to stable, circular episomes as monomers or concatemers. Over time, the number of AAV genomes per circular episome increases until it becomes stable. The format of AAV DNA contributing to the increase in concatemer size is currently uncharacterized. (B) Proposed mRNA and (C) protein kinetics of transgenes driven by the CAG, hSyn, and CamKII promoters. Created using images from BioRender.com.
Figure 5 Model of rAAV9 genome processing and transgene expression. (A) Linear single-stranded rAAV DNA is transported to the nucleus and then converted to linear double-stranded genomes by second-strand synthesis or strand annealing. Linear double-stranded genomes are converted to stable, circular episomes as monomers or concatemers. Over time, the number of AAV genomes per circular episome increases until it becomes stable. The format of AAV DNA contributing to the increase in concatemer size is currently uncharacterized. (B) Proposed mRNA and (C) protein kinetics of transgenes driven by the CAG, hSyn, and CamKII promoters. Created using images from BioRender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 1

  1. Batty, 2020, Frequency, location and nature of AAV vector insertions after long-term follow up of FVIII transgene delivery in a hemophilia A dog model [abstract], Res. Pract. Thromb. Haemost., 4, 550

Cited by

See all 46

Metadata

Authors
Hollidge, B. S., Carroll, H. B., Qian, R., Fuller, M. L., Giles, A. R., Mercer, A. C., Danos, O., Liu, Y., Bruder, J. T., & Smith, J. B.
Affiliations
Regenxbio (United States) (US)
Corresponding author
Smith, Jared B.
Venue
Frontiers in Neurology
Published
2022-11-14
Volume
13
Pages
1051559-1051559
ISSN
1664-2295 (ISSN-L)
OpenAlex
W4309012465
Cited by
45
References
27
Citations by year
2026: 20 · 2025: 15 · 2024: 6 · 2023: 4
FWCI
3.77
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Neurology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
REGENXBIO
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
AAV9, adeno-associated virus vectors, intrastriatal injection, transgene expression kinetics, striatum, synapsin promoter, CAG promoter, green fluorescent protein, episomes, concatemers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors. https://app.cochat.ai/papers/10.3389/fneur.2022.1051559
The paper
Hollidge, B. S., Carroll, H. B., Qian, R., Fuller, M. L., Giles, A. R., Mercer, A. C., Danos, O., Liu, Y., Bruder, J. T., & Smith, J. B. (2022). Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors. Frontiers in Neurology. https://doi.org/10.3389/fneur.2022.1051559

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.